Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Di Kong & Danqi Deng. (2023) A Case of Anaplastic Large Cell Lymphoma Misdiagnosed with Keloid. Clinical, Cosmetic and Investigational Dermatology 16, pages 1243-1248.
Read now
Read now
Ewelina Grywalska, Marcin Pasiarski, Barbara Sosnowska-Pasiarska, Paweł Macek, Agnieszka Rolińska, Marzena Samardakiewicz, Jarosław Ludian, Stanisław Góźdź & Jacek Roliński. (2019) Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study. Cancer Management and Research 11, pages 7605-7618.
Read now
Read now
Yijun Shen, Tong Yang, Xuemei Cao, Yifan Zhang, Li Zhao, Hua Li, Teng Zhao, Jun Xu, Hengbin Zhang, Qingsong Guo, Junli Cai, Bei Gao, Helin Yu, Sicheng Yin, Ruiwen Song, Jingsong Wu, Lingyu Guan, Guanghao Wu, Li Jin, Yong Su & Yanjun Liu. (2019) Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity. mAbs 11:6, pages 1149-1161.
Read now
Read now
Articles from other publishers (24)
Thanida Chanpong, Watee Seesuay, Wararat Chiangjong, Piamsiri Jiramornimit, Sarinthip Preedagasamzin, Korakot Atjanasuppat, Bunyada Jittorntrum, Somsak Prasongtanakij, Supannikar Tawinwung, Sulada Pukiat, Chonticha Saisawang, Suparerk Borwornpinyo, Khanit Sa-ngiamsuntorn, Wanpen Chaichumpa, Suradej Hongeng & Usanarat Anurathapan. (2023) A novel anti-membrane CD30 single-chain variable fragment discovered from the human phage library: A potential targeted immunotherapy. PLOS ONE 18:4, pages e0284708.
Crossref
Crossref
Keval Thakkar, Sonali Khurana, Yujiao Sun & Timothy N Hembree. (2023) Diabetic Ketoacidosis and Profound Insulin Resistance From Brentuximab Vedotin. Cureus.
Crossref
Crossref
Holly Cranmer, David Trueman, Elise Evers, Fionn Woodcock & Tanja Podkonjak. (2022) Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin. PharmacoEconomics - Open 6:6, pages 881-892.
Crossref
Crossref
Anagha Deshpande & Javier Munoz. (2022) Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies. Frontiers in Oncology 12.
Crossref
Crossref
Beverly A. Teicher & Joel Morris. (2022) Antibody-drug Conjugate Targets, Drugs, and Linkers. Current Cancer Drug Targets 22:6, pages 463-529.
Crossref
Crossref
M. Murali, A. R. Kumar, B. Nair, K. Pavithran, A. R. Devan, G. K. Pradeep & L. R. Nath. (2021) Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance. Clinical and Translational Oncology 24:3, pages 407-431.
Crossref
Crossref
T.I. Ionova, A.A. Amdiev, M.I. Andrievskikh, E.A. Baryakh, E.V. Vasil’ev, M.V. Volkov, E.M. Volodicheva, V.V. Ivanov, O.V. Kaverina, K.D. Kaplanov, T.Yu. Klitochenko, V.I. Kurakin, D.G. Lazareva, O.G. Larionova, K.V. Lepik, I.B. Lysenko, V.Ya. Melnichenko, R.I. Minullina, O.V. Mironov, E.N. Misyurina, N.B. Mikhailova, N.E. Mochkin, Tatyana Pavlovna Nikitina, T.S. Petrova, N.M. Porfirieva, O.A. Rukavitsyn, A.A. Samoilova, R.N. Safin, P.I. Simashova, E.G. Smirnova, N.A. Trenina, N.V. Fadeeva, G.N. Khusainova, V.L. Chang, T.V. Shelekhova & D.G. Sherstnev. (2022) The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin’s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice. Clinical oncohematology 15:1, pages 42-53.
Crossref
Crossref
Reidun Aesoy & Lars Herfindal. 2022. The Pharmacological Potential of Cyanobacteria. The Pharmacological Potential of Cyanobacteria
55
79
.
Jean-Philippe Merlio & Marshall E. Kadin. (2021) Cytokines, Genetic Lesions and Signaling Pathways in Anaplastic Large Cell Lymphomas. Cancers 13:17, pages 4256.
Crossref
Crossref
Arya A. Akhavan, Emily C. Wirtz, David W. Ollila & Nishant Bhatt. (2021) An Unusual Case of BIA-ALCL Associated with Prolonged/Complicated Biocell-Textured Expander, followed by Smooth Round Breast Implant Exposure, and Concurrent Use of Adalimumab. Plastic & Reconstructive Surgery 148:2, pages 299-303.
Crossref
Crossref
Ben Sprangers, Leonardo V. Riella & Daan Dierickx. (2021) Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review. American Journal of Kidney Diseases 78:2, pages 272-281.
Crossref
Crossref
Elissa Andraos, Joséphine Dignac & Fabienne Meggetto. (2021) NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target. Cancers 13:1, pages 144.
Crossref
Crossref
Sumiko Saito, Haruko Tashiro, Ritsu Sumiyoshi, Takuji Matsuo, Tadashi Yamamoto, Kensuke Matsumoto, Jun Ooi & Naoki Shirafuji. (2021) Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors. Medicine 100:15, pages e25576.
Crossref
Crossref
Mariana Segovia-Mendoza, Cristina Lemini, Rocio García-Becerra & Jorge Morales-Montor. 2021. Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives. Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives
11
31
.
Luca Mologni. 2021. Therapeutic Strategies to Overcome ALK Resistance in Cancer. Therapeutic Strategies to Overcome ALK Resistance in Cancer
101
121
.
Jon van der Walt, Attilio Orazi & Daniel A. ArberAlexandar Tzankov. 2020. Diagnostic Bone Marrow Haematopathology. Diagnostic Bone Marrow Haematopathology
314
339
.
Jonathan J. Lyons & Dean D. Metcalfe. (2020) Targeting Mast Cells with Biologics. Immunology and Allergy Clinics of North America 40:4, pages 667-685.
Crossref
Crossref
Chiara Borsari, Darci J. Trader, Annalisa Tait & Maria P. Costi. (2020) Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology. Journal of Medicinal Chemistry 63:5, pages 1908-1928.
Crossref
Crossref
Kianna Robinson & Venkataswarup Tiriveedhi. (2020) Perplexing Role of P-Glycoprotein in Tumor Microenvironment. Frontiers in Oncology 10.
Crossref
Crossref
Rutger C. Melchers, Rein WillemzeJoost S. P. VermaatPatty M. JansenLaurien A. Daniëls, Hein PutterMarcel W. BekkenkEllen R. M. de HaasBarbara HorvathMichelle M. van RossumCornelus J. G. Sanders, Joep C. J. M. Veraart, Maarten H. Vermeer & Koen D. Quint. (2020) Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease. Blood 135:10, pages 769-773.
Crossref
Crossref
Stefania Crisci, Raffaele Di Francia, Sara Mele, Pasquale Vitale, Giuseppina Ronga, Rosaria De Filippi, Massimiliano Berretta, Paola Rossi & Antonio Pinto. (2019) Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. Frontiers in Oncology 9.
Crossref
Crossref
Denis Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen & Gerhard Niederfellner. (2019) Acquired Resistance to Antibody-Drug Conjugates. Cancers 11:3, pages 394.
Crossref
Crossref
Gerald W. Prager, Matthias Unseld, Fredrik Waneck, Robert Mader, Fritz Wrba, Markus Raderer, Thorsten Fuereder, Phillip Staber, Ulrich Jäger, Markus Kieler, Daniela Bianconi, Mir Alireza Hoda, Lukas Baumann, Alexander Reinthaller, Walter Berger, Christoph Grimm, Heinz Kölbl, Maria Sibilia, Leonhard Müllauer & Christoph Zielinski. (2019) Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. Oncotarget 10:9, pages 942-952.
Crossref
Crossref
Neelakshi Mungra, Sandra Jordaan, Precious Hlongwane, Krupa Naran, Shivan Chetty & Stefan Barth. (2019) Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells. Oncotarget 10:8, pages 897-915.
Crossref
Crossref